Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gilead shares slump...

    Gilead shares slump after gloomy sales forecast for hep C drugs

    Written by supriya kashyap kashyap Published On 2017-02-11T10:01:52+05:30  |  Updated On 11 Feb 2017 10:01 AM IST
    Gilead shares slump after gloomy sales forecast for hep C drugs

    Gilead Sciences Inc's shares fell as much as 10 percent, after the drug maker forecast bleak sales for its hepatitis C drugs this year, underscoring the need for the company to strengthen its pipeline through acquisitions.


    Sales of the drugs, including Sovaldi and Harvoni, have slowed, missing Wall Street estimates in the past few quarters, but still account for nearly half of Gilead's total revenue.


    Chief Executive John Milligan acknowledged on Tuesday that the company had few prospects for new products over the next few years. "It makes it challenging for us to grow without an acquisition," Milligan said.


    Several analysts said Milligan's stance reflected a change in the company's M&A strategy.


    "We continue to see M&A as the primary catalyst though the level of urgency for deals is under-recognized," Barclays analysts said.


    Gilead is one of the few large drugmakers to have eschewed splurging on multi-billion dollar deals in the recent past even as M&A activity in the healthcare sector hit record levels.


    The company had $32.4 billion of cash, cash equivalents and marketable securities as of Dec. 31.


    At least 2 brokerages downgraded their ratings on the stock, while 10 cut their price targets.


    "Management desperately needs to identify candidates for Gilead's pipeline capable of changing the conversation among investors from 'How bad will it get?' to 'How good could it be?'," Cowen analysts said.


    Gilead forecast 2017 hepatitis C drug sales of $7.5 billion-$9 billion, much lower than the $12 billion Wall Street analysts had expected, due to fewer patients starting on treatments and increased competition.


    Hepatitis C, estimated to infect about 3.2 million Americans, is a viral disease that causes inflammation of the liver that can lead to liver failure.


    Sovaldi and Harvoni revolutionized treatment of the disease, helping triple the company's sales to nearly $33 billion in 2015 from 2013.


    Despite the recent slowdown in sales of hep C drugs, analysts remain largely bullish on the stock. Seventeen of 29 analysts rate the stock "buy" or higher and rest have "hold" ratings, according to Thomson Reuters data.


    Gilead's shares were down 9.5 percent at $66.18 on Wednesday, after hitting a near three-year low of $65.75. The stock was the biggest drag on the S&P 500 Index.


    "We are still of the view that Gilead can buy growth or an impactful pipeline or both, but investor patience seems to be wearing thin," Barclays analysts said.

    AcquisitionGileadHarvonihepatitis Chepatitis C drugsJohn MilliganSovaldi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok